{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T18:21:31Z","timestamp":1775586091996,"version":"3.50.1"},"reference-count":23,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004425","name":"Asian Development Bank","doi-asserted-by":"publisher","award":["R2RJ4"],"award-info":[{"award-number":["R2RJ4"]}],"id":[{"id":"10.13039\/100004425","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    Chronic kidney disease (CKD) is increasingly recognized as a global public health concern, impacting about 800 million people worldwide. Despite having different CKD etiologies, apoptosis, inflammation and fibrosis are the central mechanisms of pathogenesis. Tumor necrosis factor (TNF)- related apoptosis-inducing ligand (TRAIL) is a critical regulator of these mechanisms, suggesting a prominent role in pathogenesis and progression of CKD. Therefore, systematic mapping of the available evidence is pivotal in identifying the exact role of TRAIL and its receptors in CKD. The proposed scoping review will be conducted in line with Arksey and O\u2019Malley\u2019s methodological framework and the Joanna Briggs Institute (JBI) reviewer\u2019s manual. Accordingly, the review will be guided by the five-stage approach, namely (1) identify the research question; (2) identify relevant studies; (3) select studies; (4) chart the data; and (5) collate, summarize, and report the results. Eligibility criteria and search strategies will be formulated based on population, concept, and context (PCC) strategy. Articles published up to January 2026 will be searched using electronic databases (PubMed\/ MEDLINE, Science Direct, Scopus, CINAHL, EMBASE, Web of Science and Cochrane Library) and clinical trial registries (ClinicalTrials.gov and WHO ICTRP). Reference lists of relevant reviews retrieved from Google Scholar will also be screened for grey literature. A formal quality appraisal of the selected studies will be conducted using the mixed-method appraisal tool (MMAT version 2018). The reporting will be done following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for the Scoping Reviews checklist. The literature search is expected to commence in March 2026, followed by study selection and data extraction by April 2026. Data synthesis will be completed by June 2026. The review protocol is registered at Open Science Framework (OSF) under\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/doi.org\/10.17605\/OSF.IO\/AENBX\" xlink:type=\"simple\">https:\/\/doi.org\/10.17605\/OSF.IO\/AENBX<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0330796","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T17:31:35Z","timestamp":1775583095000},"page":"e0330796","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mapping the role of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors in chronic kidney disease: A scoping review protocol"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9271-7302","authenticated-orcid":true,"given":"Hansani","family":"Niroshika","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harshi","family":"Weerakoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nalaka","family":"Herath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosala","family":"Weerakoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasad","family":"Jayasooriya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"pone.0330796.ref001","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"pone.0330796.ref002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","article-title":"Epidemiology of chronic kidney disease: an update 2022","volume":"12","author":"CP Kovesdy","year":"2022","journal-title":"Kidney Int Suppl"},{"issue":"7","key":"pone.0330796.ref003","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/10641963.2017.1306541","article-title":"Hypertension and hyperglycemia and the combination thereof enhances the incidence of chronic kidney disease (CKD) in middle-aged and older males","volume":"39","author":"R Michishita","year":"2017","journal-title":"Clin Exp Hypertens"},{"key":"pone.0330796.ref004","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.mpmed.2019.06.010","article-title":"Epidemiology and causes of chronic kidney disease","volume":"47","author":"R Noble","year":"2019","journal-title":"Med"},{"issue":"10","key":"pone.0330796.ref005","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1681\/ASN.2014070714","article-title":"Cause of Death in Patients with Reduced Kidney Function","volume":"26","author":"S Thompson","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"pone.0330796.ref006","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.kint.2016.08.025","article-title":"Progression of chronic kidney disease: too much cellular talk causes damage","volume":"91","author":"L Gewin","year":"2017","journal-title":"Kidney Int"},{"issue":"5","key":"pone.0330796.ref007","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41581-023-00694-0","article-title":"Regulated cell death pathways in kidney disease","volume":"19","author":"AB Sanz","year":"2023","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"pone.0330796.ref008","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","article-title":"Identification and characterization of a new member of the TNF family that induces apoptosis","volume":"3","author":"SR Wiley","year":"1995","journal-title":"Immunity"},{"issue":"8","key":"pone.0330796.ref009","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/1521-4141(200208)32:8<2246::AID-IMMU2246>3.0.CO;2-6","article-title":"Characterization of the in vivo function of TNF-alpha-relatedapoptosis-inducing ligand, TRAIL\/Apo2L, using TRAIL\/Apo2L gene-deficient mice","volume":"32","author":"LM Sedger","year":"2002","journal-title":"Eur J Immunol"},{"issue":"27","key":"pone.0330796.ref010","doi-asserted-by":"crossref","first-page":"41662","DOI":"10.18632\/oncotarget.9340","article-title":"Functional TRAIL receptors in monocytes and tumor-associated macrophages: A possible targeting pathway in the tumor microenvironment","volume":"7","author":"M Liguori","year":"2016","journal-title":"Oncotarget"},{"issue":"8","key":"pone.0330796.ref011","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1093\/ndt\/gfq042","article-title":"The circulating soluble TRAIL is a negative marker for inflammation inversely associated with the mortality risk in chronic kidney disease patients","volume":"25","author":"S Liabeuf","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"pone.0330796.ref012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203716","article-title":"Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease","volume":"13","author":"MV Arcidiacono","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"pone.0330796.ref013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092952","article-title":"TRAIL deficiency contributes to diabetic nephropathy in fat-fed ApoE-\/- mice","volume":"9","author":"SP Cartland","year":"2014","journal-title":"PLoS One"},{"issue":"17","key":"pone.0330796.ref014","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1042\/CS20201004","article-title":"TRAIL treatment prevents renal morphological changes and TGF-\u03b2-induced mesenchymal transition associated with diabetic nephropathy","volume":"134","author":"B Toffoli","year":"2020","journal-title":"Clin Sci (Lond)"},{"issue":"2","key":"pone.0330796.ref015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.kint.2024.10.026","article-title":"TRAIL induces podocyte PANoptosis via death receptor 5 in diabetic kidney disease","volume":"107","author":"Z Lv","year":"2025","journal-title":"Kidney Int"},{"issue":"2","key":"pone.0330796.ref016","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00689.2016","article-title":"Urinary DcR2 is a novel biomarker for tubulointerstitial injury in patients with diabetic nephropathy","volume":"313","author":"J Chen","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"key":"pone.0330796.ref017","doi-asserted-by":"crossref","first-page":"924299","DOI":"10.3389\/fendo.2022.924299","article-title":"Cellular Senescence and Regulated Cell Death of Tubular Epithelial Cells in Diabetic Kidney Disease","volume":"13","author":"S Shen","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"pone.0330796.ref018","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"H Arksey","year":"2005","journal-title":"Int J Soc Res Methodol"},{"issue":"4","key":"pone.0330796.ref019","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.physio.2019.10.005","article-title":"Scoping reviews","volume":"105","author":"MC Harms","year":"2019","journal-title":"Physiotherapy"},{"issue":"7","key":"pone.0330796.ref020","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation","volume":"169","author":"AC Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"pone.0330796.ref021","article-title":"JBI Reviewer\u2019s Manual. 32","author":"E Aromataris","year":"2020","journal-title":"Joanna Briggs Inst."},{"issue":"1","key":"pone.0330796.ref022","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"M Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"pone.0330796.ref023","first-page":"1","author":"Q Hong","year":"2018","journal-title":"Dep Fam Med McGill"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0330796","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T17:31:41Z","timestamp":1775583101000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0330796"}},"subtitle":[],"editor":[{"given":"Jie","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0330796","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]}}}